Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells

Lenvatinib is a tyrosine kinase receptor inhibitor used to treat unresectable hepatocellular carcinoma (HCC). In this study, we investigated the antitumor effects of Lenvatinib treatment on HCC cell lines. Proliferation was examined in four HCC cell lines (HuH-7, Hep3B, Li-7, and PLC/PRF/5) using Cell Counting Kit-8 assays. Xenograft mouse models were used to assess the effects of Lenvatinib in vivo. Cell cycle, western blotting, and microRNA (miRNA) expression analyses were performed to identify the antitumor inhibitory potential of Lenvatinib on HCC cells. Lenvatinib treatment suppressed proliferation of HuH-7 and Hep3B, but not Li-7 and PLC/PRF/5 cells and induced G0/G1 cell cycle arrest and cyclin D1 downregulation in Lenvatinib-sensitive cells. Lenvatinib treatment also reduced tumor growth in HuH-7 xenograft mouse models. miRNA microarrays revealed that Lenvatinib treatment altered the expression of miRNAs in HuH7 cells and exosomes. Our results demonstrated the therapeutic potential of Lenvatinib and provide molecular mechanistic insights into its antitumor effects for treating HCC.

[1]  Liu Yang,et al.  miR-1470 regulates cell proliferation and apoptosis by targeting ALX4 in hepatocellular carcinoma. , 2019, Biochemical and biophysical research communications.

[2]  J. Akiba,et al.  Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo , 2019, AntiCancer Research.

[3]  Huajun Zhao,et al.  HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape , 2019, Cells.

[4]  Fei Wang,et al.  miR-491-5p functions as a tumor suppressor by targeting IGF2 in colorectal cancer , 2019, Cancer management and research.

[5]  Fugen Li,et al.  Exosomal microRNAs as potential biomarkers for cancer cell migration and prognosis in hepatocellular carcinoma patient-derived cell models , 2018, Oncology reports.

[6]  Hang-Seok Chang,et al.  SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer , 2018, BMC Cancer.

[7]  Yuji Yamamoto,et al.  Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models , 2018, Cancer medicine.

[8]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[9]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[10]  Chao Zeng,et al.  miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop. , 2017, Cancer letters.

[11]  Guihua Wang,et al.  Low expression of microRNA-320b correlates with tumorigenesis and unfavorable prognosis in glioma. , 2017, Oncology reports.

[12]  Chen Huang,et al.  miR-491-5p, mediated by Foxi1, functions as a tumor suppressor by targeting Wnt3a/β-catenin signaling in the development of gastric cancer , 2017, Cell Death and Disease.

[13]  Tomoyuki Suzuki,et al.  ASP5878, a Novel Inhibitor of FGFR1, 2, 3, and 4, Inhibits the Growth of FGF19-Expressing Hepatocellular Carcinoma , 2016, Molecular Cancer Therapeutics.

[14]  Tsutomu Masaki,et al.  MicroRNA profiles in various hepatocellular carcinoma cell lines , 2016, Oncology letters.

[15]  J. Lund,et al.  Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma , 2016, The oncologist.

[16]  J. Larkin,et al.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.

[17]  F. Lv,et al.  FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation , 2015, Oncotarget.

[18]  T. Masaki,et al.  MicroRNA profiles in cisplatin-induced apoptosis of hepatocellular carcinoma cells. , 2015, International journal of oncology.

[19]  Masao Iwata,et al.  Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models , 2014, Journal of thyroid research.

[20]  Raquel Urtasun,et al.  Regulation of Amphiregulin Gene Expression by β-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System , 2012, PloS one.

[21]  Xianghuo He,et al.  Macro-management of microRNAs in cell cycle progression of tumor cells and its implications in anti-cancer therapy , 2011, Acta Pharmacologica Sinica.

[22]  Y. Sekido,et al.  E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles , 2009, Clinical Cancer Research.

[23]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[24]  Y. Funahashi,et al.  Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase , 2008, Clinical Cancer Research.

[25]  Kuen-Feng Chen,et al.  Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. , 2008, Cancer research.

[26]  Yuji Yamamoto,et al.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.

[27]  H. El‐Serag,et al.  Hepatocellular carcinoma: recent trends in the United States. , 2004, Gastroenterology.

[28]  P. Hou,et al.  Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer. , 2017, American journal of cancer research.

[29]  Kuen-Feng Chen,et al.  Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. , 2010, Journal of hepatology.